IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
AIDS and Cancer Specimen Bank (ACSB)
This study has been completed.
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
National Cancer Institute (NCI)
George Washington University
University of Hawaii
University of California, San Francisco
Kaiser Permanente
Information provided by:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00587912
First received: December 24, 2007
Last updated: April 20, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to obtain clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS and non-AIDS associated malignancies.
The National Cancer Institute has set up a Bank for tissues and biological fluids from HIVpositive and HIV-negative individuals in order to have specimens available for scientists studying malignancies associated with HIV disease.
| Condition |
|---|
| Kaposi's Sarcoma AIDS Related Kaposi's Sarcoma Classical Non-Hodgkin's Lymphoma HEMATOPOIETIC SYSTEM Cancer AIDS |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | AIDS and Cancer Specimen Bank (ACSB) |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Lymphosarcoma
Soft Tissue Sarcoma
Kaposi Sarcoma
U.S. FDA Resources
Further study details as provided by Memorial Sloan Kettering Cancer Center:
Primary Outcome Measures:
- Identify and improve access to tumor tissue, biological specimens, and associated clinical outcome data that could be utilized for research by the research community at-large on the pathogenesis of HIV and non-HIV associated malignancies. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
Blood, urine, other bodily fluids (eg, pleural fluid), and tumor tissue obtained from patients.
| Enrollment: | 65 |
| Study Start Date: | June 1997 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
The overall goal of the AIDS and Cancer Specimen Bank is to obtain clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS and non- AIDS associated malignancies. These specimens will be banked and linked to a clinical data set so that experimental results obtained by analysis of specific specimens can be linked to relevant clinical data. Contents of the ACSB will be made available to researchers through an application to the National Cancer Institute. Strict patient confidentiality protection guidelines are in place for all specimens in the ACSB. The objective of this protocol is to obtain clinical specimens from potential participants in clinical trials conducted by the AIDS Malignancies Consortium, and from other patients with and without HIV infection, who have AIDS-Associated malignancies.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
The Source of specimens will include patients screened for participation on protocols conducted by the AIDS Malignancy Consortium, as well as other patients with HIV infection and cancer who are not eligible for participation in AMC trials, and patients without HIV who have malignancies associated with HIV or with immunosuppression.
Criteria
Inclusion Criteria:
- Patient > 18 years of age
- Suspected or confirmed AIDS-Associated malignancy with or without HIV infection
- Will obtain fresh tissue and/or biological fluids
- Patient signed the correct version of the informed consent
Exclusion Criteria:
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00587912
Please refer to this study by its ClinicalTrials.gov identifier: NCT00587912
Locations
| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
George Washington University
University of Hawaii
University of California, San Francisco
Kaiser Permanente
Investigators
| Principal Investigator: | David Straus, MD | Memorial Sloan Kettering Cancer Center |
More Information
Additional Information:
| Responsible Party: | David Straus, MD, Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00587912 History of Changes |
| Other Study ID Numbers: |
97-043 |
| Study First Received: | December 24, 2007 |
| Last Updated: | April 20, 2011 |
Keywords provided by Memorial Sloan Kettering Cancer Center:
|
Kaposi's Sarcoma AIDS Related Kaposi's Sarcoma Classical Non-Hodgkin's Lymphoma |
HEMATOPOIETIC SYSTEM Cancer AIDS |
Additional relevant MeSH terms:
|
Sarcoma Lymphoma, Non-Hodgkin Sarcoma, Kaposi AIDS-Related Opportunistic Infections Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Lymphoma Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Herpesviridae Infections DNA Virus Infections Virus Diseases Neoplasms, Vascular Tissue Opportunistic Infections Infection HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Parasitic Diseases Immunologic Deficiency Syndromes |
ClinicalTrials.gov processed this record on August 18, 2017